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Abstract
Background: Data on the haematological outcomes of patients who continue clozapine treatment following
neutropenia are very rare as even mild neutropenia results in mandatory discontinuation of clozapine in most
countries. However, in Iceland where clozapine monitoring is less stringent allows an observational study to be
done on the risk of agranulocytosis and neutropenia during treatment with clozapine compared with other
antipsychotics among patients with schizophrenia.
Methods: The present study is a part of a wider ongoing longitudinal study of schizophrenia in Iceland. We
identified 201 patients with schizophrenia treated with clozapine and 410 patients with schizophrenia who had
never been on clozapine by searching the electronic health records of Landspitali, the National University Hospital.
Neutrophil counts were searched in electronic databases to identify patients who developed neutropenia/
agranulocytosis and the frequency of neutrophil measurements was examined as well.
Results: The median number of days between neutrophil measurements during the first 18 weeks of clozapine
treatment was 25 days but after the first 18 weeks on the drug the median became 124 days. Thirty four cases of
neutropenia were identified during clozapine treatment with an average follow up time of 9.2 years. The majority,
24 individuals developed mild neutropenia (1500–1900 neutrophils/mm3). None of these progressed to
agranulocytosis. The remaining 10 patients developed neutropenia in the range 500–1400 /mm3 of whom one
developed agranulocytosis, three stopped clozapine use and 6 patients continued on clozapine for at least a year
without developing agranulocytosis. Unexpectedly, schizophrenia patients on other antipsychotics had an equal risk
of developing neutropenia as those on clozapine.
Conclusions: Neutropenia is common both in patients with schizophrenia on clozapine treatment and in those
never on clozapine. Therefore a large part of neutropenia during clozapine treatment is probably not caused by
clozapine. These findings have implications in assessing the balance between the risk of progression from
neutropenia to agranulocytosis against the morbidity resulting from the premature discontinuation of clozapine
under the current monitoring regulations in the US and in most of Europe.
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Background
Around 20–30% of patients with schizophrenia prove to
be treatment resistant, defined as failure to respond to
two or more antipsychotics (one of which should be an
atypical) when given an adequate dose for at least six to
eight weeks [1, 2]. Clozapine has been demonstrated to
be the drug of choice for these patients [3, 4].
Some physicians are reluctant to prescribe cloza-
pine, probably because of the relatively high burden
of adverse side effects, especially the rare but poten-
tially life-threatening agranulocytosis [4]. Even
though clozapine has a high burden of various ad-
verse side effects we have reported that over 70% of
patients that commence clozapine treatment in
Iceland remain on it long term [5]. A pharmacoge-
netic test for agranulocytosis with adequate predict-
ive validity is unlikely and would likely present
ethical challenges [6, 7]. The risk of agranulocytosis
is managed in most developed countries by
mandatory blood monitoring for patients on cloza-
pine [8]. In the UK patients taking clozapine must
enrol in a clozapine monitoring service where it is
obligatory to be monitored weekly for the first
18 weeks of treatment. During the next 34 weeks
neutrophil monitoring is done every other week and
then monthly after the first year of monitoring has
passed [9]. The risk of agranulocytosis is estimated
to be 0.68% but after the first year this risk drops by
a factor of 10 [10, 11]. The mortality when agranulo-
cytosis develops has been estimated to be 2.7–3.1%
[12, 13]. Therefore the absolute mortality of patients
on clozapine due to agranulocytosis is very low or
around 0.02% or two out of ten thousand patients.
Regular blood monitoring has been reported to be
effective in reducing this risk [14] but it also places
limitations on the use of clozapine in three ways:
firstly, by excluding patients living in areas where
clozapine monitoring systems are not in place, sec-
ondly by making physicians reluctant to prescribe it,
thirdly by placing an additional burden on patients,
and lastly by requiring that any patient whose neu-
trophil count drops below 1500/mm3 discontinues
clozapine permanently [15]. There is growing evi-
dence that clozapine treatment is associated with
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Fig. 1 Description of study cohort in the study period of 1.1.1998 – 21.11.2014
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reduced mortality compared to treatment with other
antipsychotics [16].
Monitoring systems are in place in the United States
and in most European countries but the regulation of
clozapine use varies substantially between countries [8].
Some countries, including Iceland, have taken a more
flexible stance and not enforced such regulations for clo-
zapine prescriptions in view of the fact that there is no
other alternative drug available with similar efficacy for
treatment resistant schizophrenia, as well as the practical
difficulties of regular monitoring in remote areas.
People of certain ethnic groups, such as Yemenite
Jews and 25–50% of black Africans, commonly have
an intrinsic low neutrophil count in the range of 1.0
– 1.5 without any observed adverse clinical effects
such as more frequent bacterial infections. These in-
dividuals are said to have benign ethnic neutropenia
(BEN) [17]. According to the UK guidelines, clozapine
treatment is stopped when neutrophil count falls
below 1500/mm3. By following this recommendation
it can be quite challenging to provide clozapine to
these patients. This reality was acknowledged in the
USA in the recent change of recommendations in Oc-
tober 2015 by the Food and Drug Administration
(FDA) with a relaxation of the requirement to stop
clozapine treatment when the neutrophil count falls
below 1000/mm3 [18]. Prescribers can now continue
to prescribe clozapine treatment for patients with an
neutrophil count less than 1000/mm3 if the pre-
scriber’s evaluation is that the benefits of clozapine
therapy outweigh the risk of severe neutropenia [18].
The risks and benefits of changing or abolishing cloza-
pine monitoring are difficult to quantify owing to a lack
of evidence on the natural course of neutrophil counts
in the absence of a monitoring programme.
The aim of this study
To analyze the risk of neutropenia and further the pro-
gression to agranulocytosis in a sample of patients with
schizophrenia in Iceland, where it is not mandatory to
provide blood samples at certain intervals in order to get
clozapine dispensed.
Methods
Study population
The present study is a part of a wider ongoing longitu-
dinal study of psychotic disorders in the Landspitali Uni-
versity Hospital (LUH) department of psychiatry
focusing on patients with schizophrenia and bipolar dis-
order. Patients have been recruited to the study in sev-
eral waves from 1986–2014. The majority of inpatients
and outpatients at LUH with schizophrenia have been
invited to take part in the study. Almost all the patients
in study have been admitted to LUH. Most of the
patients were recruited in 2000–2004. In this study we
looked at patients in the LUH cohort who were alive on
the 1.1.2003 and who had a confirmed diagnosis of
schizophrenia according to the Research Diagnostic Cri-
teria, assessed using the “Schedules for Affective Dis-
order and Schizophrenia-Lifetime version” (SADS-L)
[19]. In total there were 611 patients who met the cri-
teria (Fig. 1).
LUH introduced electronic health records (EHR) in
1998 but older health records are available on paper.
Subsequently the proportion of medical, psychology and
nursing data in the EHR has been steadily growing and
currently includes almost all patient data in LUH.
LUH is the only tertiary hospital for mental health ser-
vices in Iceland. LUH also provides secondary psychi-
atric services and psychiatric inpatient beds for over 90%
of the population, the proportion being even higher for
treatment resistant patients. Therefore the overwhelming
majority of all Icelandic patients with schizophrenia who
have ever taken clozapine have been in regular contact
with mental health services or other services at LUH.
Case identification
To identify patients that have used clozapine we used a
keyword search in the EHR for the words “clozapin”,
“closapin” and “Leponex”. The “e” at the end of clozapin
was skipped because of possible spelling errors in the
EMR but a keyword search of “clozapin” will find both
“clozapin” and “Clozapine”. Leponex was the only brand
name of clozapine in Iceland during the study period.
All medical notes with the clozapine keywords were
reviewed to confirm clozapine use. Wherever insufficient
documentation of prior psychotic disorder and medica-
tion use was present in the EHR, the paper medical re-
cords were reviewed. We identified 201 patients with
schizophrenia. The remaining 410 patients with schizo-
phrenia who had never used clozapine but had been
treated with other antipsychotics comprised the com-
parison group. Information on the first period of cloza-
pine treatment for patients with schizophrenia was
available for 195 patients out of 201.
Frequency of blood tests
The frequency of blood measurements was analyzed for
patients treated with clozapine from 1.1.1998 until 21.11
2014. The frequency of measurements was calculated by
dividing the total time on clozapine treatment by the
number of neutrophil measurements. The frequency of
measurements during the first 18 weeks was analyzed
separately from the subsequent time-period. The fre-
quency analysis for neutrophil measurements only in-
cluded patients who were using clozapine for the first
time. Eighteen patients for whom the clozapine start
date was not known to an exact date and four patients
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who did not live in the Reykjavik metropolitan area,
where LUH is situated, were excluded from the blood
monitoring analyzes for the first 18 weeks.
Identification of neutropenia or agranulocytosis
We searched electronically all available results of blood
measurements at LUH for neutrophil counts. The LUH
database is linked to regional laboratory databases in
Iceland using the Icelandic social security number (ken-
nitala) which is a unique personal identifier for each Ice-
lander. Among these is the database in the regional
hospital in Akureyri where Iceland’s only other depart-
ment of psychiatry is located in Iceland’s second largest
hospital. This department provides mental health ser-
vices for the remaining 10% of Iceland’s population. We
also used a keyword search in the EHR to identify add-
itional cases with the following keywords to find medical
notes where neutropenia or agranulocytosis were men-
tioned; “Neutropaenia”, “neutropaenia”, “neutropenia”,
“leucopaenia”, “leucopenia”, “kyrningafæ”, “hvítkornafæ”.
The complete medical notes, electronic as well as on
paper, were reviewed in order to confirm the diagnosis.
Neutrophil count in the range of 1500/mm3 – 1900/
mm3 was defined as mild neutropenia. Icelandic guide-
lines recommend that if neutrophils counts are 1500/
mm3-1900/mm3 then neutrophil monitoring should be
increased to twice every week until the neutrophil count
rises to 2000/mm3 or above, whereas if neutrophils fall
below 1500/mm3 treatment should be stopped [15, 20].
Neutrophil count in the range 1000/mm3-1400/mm3
was defined as moderate neutropenia and neutrophil
count in the range of 500/mm3-900/mm3 as severe neu-
tropenia [20]. Agranulocytosis literally means the ab-
sence of circulating granulocytes but the term is used in
clinical practice in psychiatry when the neutrophil count
falls below 500/mm3 [20]. Neutrophil counts in Iceland
are rounded to the nearest 100/mm3.
The STROBE guidelines for reporting the results of
observational studies were followed. Statistical analyses
were performed with STATA, version 13. A Cox propor-
tional hazard model was used to assess factors associated
with neutropenia. One patient was excluded from the
Cox proportional hazards model because he used cloza-
pine only for one day.
Results
Neutrophil monitoring
In Iceland the guidelines for neutrophil monitoring rec-
ommend weekly neutrophil counts for the first 18 weeks
and monthly subsequently, but these guidelines are not
enforced in a mandatory way [15]. Table 1 describes the
frequency of neutrophil measurements after clozapine
treatment was started. During the first 18 weeks of treat-
ment a total of 16 out of 83 patients discontinued
clozapine. Neutrophils were measured weekly or more
often for only 12 out of 83 patients (14.4%). Neutrophil
measurements were performed every 5 weeks or less for
22 patients (26.5%) and 7 patients had no neutrophil mea-
surements done. The mean number of days between neu-
trophil measurements was 25 days (SD = 28) and the
median number of days between blood tests was 18 days.
Only 6 out of 160 patients (3.8%) had at least monthly
measurements of neutrophils carried out in line with guide-
lines. The median number of days between neutrophil mea-
surements was 124 days. If the 7 patients who had no
neutrophil measurements done are excluded the mean
number of days between measurements is 229 (SD = 329).
Progression from neutropenia to agranulocytosis
Table 2 shows how frequently neutropenia progressed to
agranulocytosis in our sample. For mild to moderate neu-
tropenia (1000-1900/mm3) no progression to agranulo-
cytosis was observed for 32 cases. If we only include
patients that stayed on clozapine for at least one year fol-
lowing mild to moderate neutropenia then none of 28 pa-
tients developed agranulocytosis. For patients with
moderate to severe neutropenia (<1500/mm3) one patient
out of 10 developed agranulocytosis. It is worth noting
that only 2 out of 8 (25%) patients with moderate neutro-
penia discontinued clozapine compared with 28.8% dis-
continuation for all patients ever prescribed clozapine for
treatment resistant schizophrenia in our sample.
Neutropenia in patients with schizophrenia
Table 3 describes the results of neutrophil measure-
ments with regard to low neutrophil count in the period
1.1.1998 – 21.11.2014. We found only one 56 year old
Table 1 Frequency of neutrophil measurements during
clozapine treatment
Measurements n %
First 18 weeks (n = 83)
Weekly 12 14.5
Every 1–2 weeks 22 26.5
Every 2–3 weeks 15 18.1
Every 3–4 weeks 6 7.2
Every 4–5 weeks 6 7.2
Less than every 5 weeks 22 26.5
After 18 weeks (n = 160)
Monthly 6 3.8
Every 1–2 months 33 20.6
Every 2–3 months 25 15.0
Every 3–6 months 31 19.4
Every 6-12months 37 21.3
Less than every year 31 20.0
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patient on clozapine whose neutrophils dropped
below 500/mm3, a count clinically defined as agran-
ulocytosis. Clozapine was identified as the most likely
contributing factor. Since this patient had been on
clozapine for 28 years when the agranulocytosis de-
veloped it cannot be excluded that unknown age-
related causes were at play [11, 12]. Neutrophil mea-
surements in the moderate to severe range of 500-
1400/mm3 were found in 9 patients in the clozapine
group or 4.8% of the cohort, on all occasions these
were 900/mm3 and above. Moderate to severe neutro-
penia in the never-on-clozapine group was found in
23 patients or 5.8% of the cohort, and all the neutro-
phil counts were 800/mm3 and above.
Patients in the never-on-clozapine group proved to
have a similar risk of developing agranulocytosis in the
long term since four patients out of 400 (1%) developed
agranulocytosis during the same period of observation.
However, two out of four did develop agranulocytosis
while on cytotoxic treatment due to cancer. The third
case was clinically thought to have been caused by inter-
feron treatment for hepatitis C. A likely cause could not
be identified in the fourth case but possible contributing
factors were alcohol abuse, malnutrition and hepatitis C.
Table 4 shows Cox proportional hazards models explor-
ing the factors associated with detecting various degrees
of neutropenia. When the outcome under scrutiny was
neutrophils in the range of 0-1900/mm3 then neutropenia
was associated with more frequent testing, younger age
and female sex. Being on clozapine was not significantly
associated with risk for developing neutropenia.
Discussion
Neutrophil monitoring in Iceland was far less frequent
than guidelines recommend. Neutropenia was equally
commonly observed in the clozapine group as in the
group that had never used clozapine, although mild neu-
tropenia was more common in patients on clozapine. Of
the eight patients on clozapine who developed a moder-
ate neutropenia (neutrophils 1000 – 1400/mm3), which
would have resulted in mandatory cessation of clozapine
in the UK, only two discontinued clozapine. The other
six remained on clozapine a year later and none of these
six suffered a further episode of neutropenia. Of two pa-
tients whose neutrophil count fell below 1000/mm3, one
went on to develop agranulocytosis, having been of clo-
zapine for 28 years.
The occurrence of mild (12.8%), moderate (4.3%) and
severe neutropenia (0.5%) was fairly commonly identified
in patients on clozapine despite the low frequency of
measurements. Since more frequent measurements were
significantly associated with neutropenia, it is likely that
the occurrence of mild to moderate neutropenia would
Table 2 Progression of lowest neutrophil count to agranulocytosis
Lowest neutrophil count (excluding counts taken during
episode of agranulocytosis)
Amber: Mild neutropenia
1500-1900/mm3
Red: Moderate neutropenia
1000-1400/mm3
Severe neutropenia
500-900/mm3
n = 24 n = 8 n = 2
One year after lowest level of neutropenia
Still on Clozapine 22 6 0
Clozapine discontinued 2 2 1
Developed agranulocytosis (and then discontinued) 0 0 1
Clozapine and agranulocytosis status unknown 0 0 0
Three years after lowest level of neutropenia
Still on Clozapine 18 4 0
Clozapine discontinued 3 2 1
Developed agranulocytosis (and then discontinued) 0 0 1
Clozapine and agranulocytosis status unknown 3 2 0
Table 3 Lowest neutrophil count in the clozapine group and
never-on-clozapine group
On clozapine Never-on-clozapine
Average age at follow up [Years] 51.2 58.1
Average number of neutrophil
measurements per patient
32.4 15.8
Average time of follow up [Years] 9.2 13.8
n = 188 % n = 400 %
No neutrophil measurements
performed in time period
6 3.2 8 2.0
Never neutropenia, neutrophils
2000/mm3 or higher
148 78.7 335 83.8
Mild neutropenia, neutrophils
1500-1900/mm3
24 12.8 30 7.5
Moderate neutropenia,
neutrophils 1000-1400/mm3
8 4.3 20 5.0
Severe neutropenia,
neutrophils 500-900/mm3
1 0.5 3 0.8
Agranulocytosis, neutrophils
0-400/mm3
1 0.5 4 1.0
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have been higher if the frequency of measurements had
been in line with guidelines.
Moderate (5%) and severe neutropenia (0.8%) was
more common in patients with schizophrenia who
had never been on clozapine despite having neutro-
phil counts done around half as frequently as those
on clozapine. Only mild neutropenia was found
more frequently in clozapine-treated patients than in
those never on clozapine.
It came as a surprise that being on clozapine was not
associated with neutropenia in the range of 0-1400/
mm3. For mild neutropenia in the range 1500-1900/
mm3 being on clozapine was, on the other hand, signifi-
cantly associated with almost doubling of the risk for
neutropenia (hazard ratio of 1.86). Therefore, treat-
ment with clozapine seemed to predict mild neutro-
penia, a phenomenon which is usually clinically
insignificant but that can probably increase the likeli-
hood of clozapine treatment being discontinued. Fe-
males had a higher risk of developing neutropenia
with a hazard ratio ranging from 1.70-2.00, depending
on the neutropenia range under observation. It has
been reported that agranulocytosis during clozapine
treatment is more common among females [12].
Neutropenia was also significantly more common with
lower age which is in line with what has been shown
in larger studies [11].
It can be concluded that most of the neutropenic
episodes in our sample were transient and of no ob-
servable clinical significance. However, of those devel-
oping mild neutropenia (neutrophils 1500 – 1900/
mm3), none subsequently developed agranulocytosis.
One study has reported that the rate of neutropenia
during clozapine treatment was 11.8% as compared to
17.6% for those on second generation antipsychotics
[21]. These results concur with ours and indicate that
mild to moderate neutropenia is not a good predictor
for clozapine induced agranulocytosis.
In our never-on-clozapine group four cases of agran-
ulocytosis were identified and in three cases a plausible
explanation was identified but the main cause was
speculative in the fourth case. If that patient had been
on clozapine then the agranulocytosis would almost cer-
tainly have been attributed to clozapine treatment be-
cause no other probable causes were found. The risk of
neutropenia in the clozapine group was similar to that
in the never-on-clozapine group, indicating that in many
if not most instances of neutropenia during clozapine
Table 4 Cox proportional hazards model with possible factors associated with detecting moderate to severe neutropenia and
agranulocytosis
Hazard Ratio Standard Error Z-Score 95% CI P-value
A. Neutrophils 0 - 1900/mm3
Patient on clozapine 1.33 0.33 1.14 0.81-2.18 0.25
Sex (female) 1.82 0.40 2.76 1.19-2.80 0.01
Average age at risk 0.97 0.01 −3.75 0.96-0.99 <0.001
Measurements per year 1.14 0.02 6.32 1.09-1.18 <0.001
B. Neutrophils 0 – 1400/mm3
(equivalent to red result)
Patient on clozapine 0.74 0.33 −0.68 0.31-1.76 0.50
Sex (female) 2.00 0.67 2.08 1.04-3.88 0.04
Average age at risk 0.98 0.01 −1.47 0.96-1.00 0.14
Measurements per year 1.17 0.04 4.66 1.10-1.26 <0.001
C. Neutrophils 1000 - 1900/mm3
Patient on clozapine 1.44 0.37 1.39 0.86-2.40 0.18
Sex (female) 1.76 0.41 2.46 1.12-2.77 0.03
Average age at risk 0.97 0.01 −3.85 0.95-0.98 <0.001
Measurements per year 1.13 0.02 5.98 1.09-1.18 <0.001
D. Neutrophils 1500 – 1900/mm3
(equivalent to amber result)
Patient on clozapine 1.86 0.58 1.99 1.00-3.43 0.05
Sex (female) 1.70 0.49 1.85 0.97-3.00 0.09
Average age at risk 0.96 0.01 −3.70 0.94-0.98 <0.001
Measurements per year 1.12 0.03 4.62 1.06-1.17 <0.001
A) n = 587, 89 cases. B) n = 587, 37 cases. C) n = 587, 80 cases. D) n = 587, 52 cases
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treatment observed neutropenia may in fact not be
caused by the clozapine treatment.
The progression from neutropenia to agranulocytosis
was low in our sample. When we look at patients that had
ever developed neutropenia in the range of 500–1900/
mm3 and had used clozapine for at least a year after devel-
oping neutropenia or agranulocytosis, then only one pa-
tient out of 29 (3.4%) progressed to agranulocytosis. These
results should though be interpreted with caution because
the sample is small and we note that a 95% confidence
interval for one event in 32 cases is 0 to 9.5%. The pro-
gression rate of neutropenia to agranulocytosis for pa-
tients with neutropenia in the more restrictive range of
500-1400/mm3 who continued to take clozapine for at
least a year after developing neutropenia, was 1 out 7
(14.2%). Most guidelines recommend stopping clozapine
treatment when neutrophils fall below 1500/mm3 so such
data on patients who continue on clozapine following a
“red result” is not often available. In a study by Hummer
et al. 8 out of 68 patients were diagnosed with transient
neutropenia that resolved without any change in treat-
ment but the average neutrophil count was in the mild
neutropenia range, 1780/mm3 [22].
The frequency of neutrophil measurements in Iceland
during the first 18 weeks of treatment proved to be far
lower than guidelines recommend, the median time be-
tween measurements being 18 days instead of weekly. The
frequency of neutrophil measurements after the first
18 weeks were also far from what guidelines suggest, the
median time between measurements being 124 days in-
stead of monthly. The infrequent neutrophil measure-
ments did, however, not lead to more frequent
agranulocytosis than expected, and the only patient who
developed agranulocytosis did so after being on clozapine
for over 28 years and recovered fully. It is possible that the
inclination to accept flexible neutrophil monitoring,
accepting that many treatment resistant patients find it
difficult, unpleasant or costly to turn up weekly for blood
tests as outpatients, may have contributed to a higher pro-
portion of patients staying on clozapine long term in
Iceland than reported in some other studies [23, 24].
There are some limitations in our dataset. When analyz-
ing the neutrophil monitoring data we had access to the
blood test databases in LUH and the regional hospital in
Akureyri. There are two private blood test facilities that
we did not have access to and it is possible that some
blood measurements were done there. However most pa-
tients with schizophrenia and nearly all those on clozapine
are followed up from the LUH. Some neutrophil measure-
ments in the database may not have been requested for
the purpose of clozapine blood monitoring but for other
medical reasons. Therefore the true neutrophil monitoring
associated with clozapine may be a little bit more or less
than we state in the results. The true prevalence of
neutropenia might also be underestimated if it had been
diagnosed in the private blood test facilities.
It is likely that many patients stop clozapine treatment be-
cause of low neutrophil measurements despite the risk of
agranulocytosis being small in mild to moderate neutro-
penia. Our data suggest that the majority of patients who
stop clozapine treatment after falling into the “red zone”
(neutrophils < 1500/mm3) would probably not develop
agranulocytosis were they to remain on treatment, particu-
larly if their neutropenia is in the 1000-1500/mm3 range.
Clozapine rechallenge should be assessed as an option in
those patients if no other treatment has had the same ob-
served clinical treatment effect as clozapine. The reduced
mortality associated with clozapine treatment is substantial
[16] and this is likely to outweigh the small risk of agranulo-
cytosis in patients who continue clozapine treatment despite
mild to moderate neutropenia. The risk of dying from
agranulocytosis on clozapine has been estimated to be
0.02% [10–13]. We can contrast that risk to the risk of dying
in a road traffic accident in Europe over a 40 year period
which has been reported to be 0.37% (1- (1–9.3/100.000)40)
[25]. Therefore, in Europe a patient on clozapine for 40 years
has an 18.5 times (0.37%/0.02%) higher risk of dying in a
road traffic accident than of dying from agranulocytosis.
There is a large population of schizophrenia patients
who are currently suboptimally treated; having previ-
ously made a response to clozapine that was subse-
quently discontinued due to neutropenia. Particularly
where the neutropenia was in the 1000–1500 range, con-
sideration should be given for clozapine rechallenge in
these cases, bearing in mind that 80% of patients can be
successfully challenged with careful patient selection and
monitoring [26]. There is a strong case for actively seek-
ing out such patients for clozapine rechallenge, and this
approach has been shown to be successful [27].
Conclusions
Our data would support revisions to current European
guidelines, as those called for by Cohen [28]. Specifically,
our results suggest that consideration could be given to
reducing the lower limit of the amber range, whereby
clozapine can be continued with additional monitoring,
from 1500 to 1000. This change would result in a much
lower rate of clozapine discontinuation, and our findings
suggest that the progression to agranulocytosis would
remain a rare event. Such a limit has been introduced in
the UK for patients with benign ethnic neutropenia [29]
and is in line with the new FDA guidelines regarding
clozapine monitoring [18].
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